Jinle Han

机构：CTI BioPharma (Italy), Beijing Wantai Biological Pharmacy (China)

发表论文 27 篇 · 总被引 745 次 · h-index 10

代表论文

• Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials (2022 · The Lancet Respiratory Medicine · 被引 145)
• A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2 (2022 · 中国科学通报：英文版 · 被引 130)
• Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade (2022 · Journal for ImmunoTherapy of Cancer · 被引 76)
• Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2023 · The Lancet Respiratory Medicine · 被引 74)
• ORF7 of Varicella-Zoster Virus Is a Neurotropic Factor (2012 · Journal of Virology · 被引 57)
• Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16 (2020 · Cell Host & Microbe · 被引 34)